Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.
复制标题
DOI：
10.1016/j.jtct.2021.08.014
复制
发表时间：
2021-11
影响因子：
3.2
通讯作者：
Smith SM
中科院分区：
文献类型：
--
作者：
Riedell PA;Hamadani M;Ahn KW;Litovich C;Murthy GSG;Locke FL;Brunstein CG;Merryman RW;Stiff PJ;Pawarode A;Nishihori T;Kharfan-Dabaja MA;Herrera AF;Sauter CS;Smith SM
虽然自体造血细胞移植（autoHCT）已成为一线套细胞淋巴瘤（MCL）患者的常见做法，但关于自体造血细胞移植使用趋势和相关结果的数据有限。该研究利用国际血液和骨髓移植研究中心的数据库来评估2000年1月至2018年12月期间诊断为MCL的12个月内接受autoHCT的≥18岁成年人的生存结果和移植利用。将2000-2018年的19年时间分为2000-2004年、2005-2009年、2010-2014年和2015-2018年4个时间段，共纳入5082例患者。为了评估移植利用模式，我们将来自SEER 21数据库的MCL发病率与CIBMTR报告的MCL诊断后12个月内的自体hct活动相结合。主要结局包括总生存期（OS）和干细胞移植利用率。1年非复发死亡率累积发生率从最早队列（2000-2004年）的7%下降到最新队列（2015-2018年）的2%。反映这一趋势的是，OS结果随着时间的推移而不断改善，其中3年OS在最早的队列中为72%，在最新的队列中提高到86%。此外，我们注意到从2001年到2018年，自体hct的使用率有所增加，特别是在≤65岁的患者中。这项大型回顾性分析强调了MCL患者的使用趋势和自体hct结果，并强调了优化移植前和移植后治疗策略以提高生存结果的必要性。利用国际血液和骨髓移植研究中心的数据库，我们证明，随着时间的推移，接受一线巩固性自体造血细胞移植（autoHCT）的套细胞淋巴瘤（MCL）患者的生存率有所提高，尽管淋巴瘤仍然是死亡的主要原因。AutoHCT作为一线巩固似乎仅用于少数MCL患者。
While autologous hematopoietic cell transplant (autoHCT) has become a common practice for eligible patients in the front-line setting with mantle cell lymphoma (MCL), there are limited data regarding trends in autoHCT utilization and associated outcomes. This study utilized the Center for International Blood and Marrow Transplant Research database to evaluate survival outcomes and transplant utilization in adults age ≥ 18 years-old who underwent autoHCT within 12-months of MCL diagnosis between January 2000 and December 2018. The 19-year period from 2000–2018 was divided into 4 separate intervals, 2000–2004, 2005–2009, 2010–2014, and 2015–2018, and encompassed 5082 patients. To evaluate transplant utilization patterns, we combined MCL incidence derived from the SEER 21 database with CIBMTR reported autoHCT activity within 12-months of MCL diagnosis. Primary outcomes included overall survival (OS) along with the stem cell transplant utilization rate. The cumulative incidence of non-relapse mortality at 1-year decreased from 7% in the earliest cohort (2000–2004) to 2% in the latest cohort (2015–2018). Mirroring this trend, OS outcomes continually improved with time, whereby the 3-year OS was 72% in the earliest cohort and improved to 86% in the latest cohort. Additionally, we noted an increase in autoHCT utilization from 2001 to 2018, particularly in patients ≤ 65 years old. This large retrospective analysis highlights utilization trends and autoHCT outcomes in patients with MCL and emphasizes the need to optimize pre- and post-transplant treatment strategies to enhance survival outcomes. Using the Center for International Blood and Marrow Transplant Research database, we demonstrate that over time survival for mantle cell lymphoma (MCL) patients undergoing front-line consolidative autologous hematopoietic cell transplant (autoHCT) has improved, though lymphoma remains the primary cause of death. AutoHCT as front-line consolidation appears to be utilized in only a minority of MCL patients.
登录
查看更多内容
影响因子：
20.3
作者：
Dreyling, M;Lenz, G;Hiddemann, W
通讯作者：
Hiddemann, W
影响因子：
45.3
作者：
Fenske, Timothy S.;Zhang, Mei-Jie;Hari, Parameswaran N.
通讯作者：
Hari, Parameswaran N.
影响因子：
6.2
作者：
Joshua, Thomas V.;Rizzo, J. Douglas;Zhang, Mei-Jie;Hari, Parameswaran N.;Kurian, Seira;Pasquini, Marcelo;Majhail, Navneet S.;Lee, Stephanie J.;Horowitz, Mary M.
通讯作者：
Horowitz, Mary M.
DOI：
10.1056/nejmoa1306220
发表时间：
2013-08-08
期刊：
The New England journal of medicine
影响因子：
--
作者：
Wang ML;Rule S;Martin P;Goy A;Auer R;Kahl BS;Jurczak W;Advani RH;Romaguera JE;Williams ME;Barrientos JC;Chmielowska E;Radford J;Stilgenbauer S;Dreyling M;Jedrzejczak WW;Johnson P;Spurgeon SE;Li L;Zhang L;Newberry K;Ou Z;Cheng N;Fang B;McGreivy J;Clow F;Buggy JJ;Chang BY;Beaupre DM;Kunkel LA;Blum KA
通讯作者：
Blum KA
影响因子：
45.3
作者：
Lenz, G;Dreyling, M;Hiddemann, W
通讯作者：
Hiddemann, W